JP2007530017A - ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 - Google Patents
ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 Download PDFInfo
- Publication number
- JP2007530017A JP2007530017A JP2007501815A JP2007501815A JP2007530017A JP 2007530017 A JP2007530017 A JP 2007530017A JP 2007501815 A JP2007501815 A JP 2007501815A JP 2007501815 A JP2007501815 A JP 2007501815A JP 2007530017 A JP2007530017 A JP 2007530017A
- Authority
- JP
- Japan
- Prior art keywords
- pik3ca
- seq
- mutation
- body sample
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 105
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 58
- 201000011510 cancer Diseases 0.000 title claims abstract description 19
- 101150063858 Pik3ca gene Proteins 0.000 title description 5
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims abstract description 84
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims abstract description 52
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 13
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 73
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 36
- 238000012360 testing method Methods 0.000 claims description 31
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000012163 sequencing technique Methods 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 239000002246 antineoplastic agent Substances 0.000 claims description 15
- 108091026890 Coding region Proteins 0.000 claims description 14
- 229940127089 cytotoxic agent Drugs 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000002441 reversible effect Effects 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 108020004459 Small interfering RNA Proteins 0.000 claims description 11
- 108700024394 Exon Proteins 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 206010061309 Neoplasm progression Diseases 0.000 claims description 8
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 8
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000005751 tumor progression Effects 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 102200085641 rs121913273 Human genes 0.000 claims description 6
- 102200085789 rs121913279 Human genes 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 102200085639 rs104886003 Human genes 0.000 claims description 5
- 102200085792 rs121913286 Human genes 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 4
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 claims description 4
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 claims description 4
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 102000057995 human PIK3CA Human genes 0.000 claims description 4
- 230000037439 somatic mutation Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 101000721646 Homo sapiens Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma Proteins 0.000 claims description 3
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 claims description 3
- 101000721642 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 claims description 3
- 101000721645 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Proteins 0.000 claims description 3
- 102100025063 Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma Human genes 0.000 claims description 3
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 claims description 3
- 102100025058 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Human genes 0.000 claims description 3
- 102100025059 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Human genes 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 3
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical group C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 3
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 claims description 2
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 claims description 2
- 101000605014 Homo sapiens Putative L-type amino acid transporter 1-like protein MLAS Proteins 0.000 claims description 2
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 claims description 2
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 claims description 2
- 101000796673 Homo sapiens Transformation/transcription domain-associated protein Proteins 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 102100038206 Putative L-type amino acid transporter 1-like protein MLAS Human genes 0.000 claims description 2
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 claims description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims description 2
- 102100032762 Transformation/transcription domain-associated protein Human genes 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 210000004671 cell-free system Anatomy 0.000 claims description 2
- 210000002445 nipple Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 102200085622 rs121913272 Human genes 0.000 claims description 2
- 102200085790 rs121913281 Human genes 0.000 claims description 2
- 102200085787 rs121913283 Human genes 0.000 claims description 2
- 102200115761 rs35495399 Human genes 0.000 claims description 2
- 102200085697 rs772110575 Human genes 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 36
- 108091007960 PI3Ks Proteins 0.000 abstract description 25
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract description 6
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract description 5
- 108700020796 Oncogene Proteins 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 102000043276 Oncogene Human genes 0.000 abstract description 2
- 210000001072 colon Anatomy 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 230000009368 gene silencing by RNA Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000033607 mismatch repair Effects 0.000 description 3
- -1 neocartinostatin Chemical compound 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 2
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100020824 Serine-protein kinase ATM Human genes 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000228254 Aspergillus restrictus Species 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 101100520033 Dictyostelium discoideum pikC gene Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101100352301 Homo sapiens PIK3CD gene Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100339600 Mus musculus Hprt1 gene Proteins 0.000 description 1
- 241000272144 Naja atra Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 101150026284 PIK3CD gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000003946 Saponaria officinalis Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003497 anti-pneumococcal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000013489 benign neoplasm of large intestine Diseases 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- NUSQOFAKCBLANB-UHFFFAOYSA-N phthalocyanine tetrasulfonic acid Chemical compound C12=CC(S(=O)(=O)O)=CC=C2C(N=C2NC(C3=CC=C(C=C32)S(O)(=O)=O)=N2)=NC1=NC([C]1C=CC(=CC1=1)S(O)(=O)=O)=NC=1N=C1[C]3C=CC(S(O)(=O)=O)=CC3=C2N1 NUSQOFAKCBLANB-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000027174 regulation of B cell differentiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54888604P | 2004-03-02 | 2004-03-02 | |
| PCT/US2005/005193 WO2005091849A2 (en) | 2004-03-02 | 2005-02-18 | Mutations of the pik3ca gene in human cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012052427A Division JP5336620B2 (ja) | 2004-03-02 | 2012-03-09 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007530017A true JP2007530017A (ja) | 2007-11-01 |
Family
ID=35056655
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501815A Withdrawn JP2007530017A (ja) | 2004-03-02 | 2005-02-18 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2012052427A Expired - Lifetime JP5336620B2 (ja) | 2004-03-02 | 2012-03-09 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2013100073A Expired - Lifetime JP5894110B2 (ja) | 2004-03-02 | 2013-05-10 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2015245769A Expired - Lifetime JP6250017B2 (ja) | 2004-03-02 | 2015-12-17 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2017202265A Expired - Lifetime JP6395917B2 (ja) | 2004-03-02 | 2017-10-19 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2018090580A Expired - Lifetime JP6695381B2 (ja) | 2004-03-02 | 2018-05-09 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2019201128A Expired - Lifetime JP6694543B2 (ja) | 2004-03-02 | 2019-11-06 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2020038337A Expired - Lifetime JP7169315B2 (ja) | 2004-03-02 | 2020-03-06 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2020078786A Expired - Lifetime JP7001735B2 (ja) | 2004-03-02 | 2020-04-28 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2022022542A Expired - Lifetime JP7304987B2 (ja) | 2004-03-02 | 2022-02-17 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012052427A Expired - Lifetime JP5336620B2 (ja) | 2004-03-02 | 2012-03-09 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2013100073A Expired - Lifetime JP5894110B2 (ja) | 2004-03-02 | 2013-05-10 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2015245769A Expired - Lifetime JP6250017B2 (ja) | 2004-03-02 | 2015-12-17 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2017202265A Expired - Lifetime JP6395917B2 (ja) | 2004-03-02 | 2017-10-19 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2018090580A Expired - Lifetime JP6695381B2 (ja) | 2004-03-02 | 2018-05-09 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2019201128A Expired - Lifetime JP6694543B2 (ja) | 2004-03-02 | 2019-11-06 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2020038337A Expired - Lifetime JP7169315B2 (ja) | 2004-03-02 | 2020-03-06 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2020078786A Expired - Lifetime JP7001735B2 (ja) | 2004-03-02 | 2020-04-28 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| JP2022022542A Expired - Lifetime JP7304987B2 (ja) | 2004-03-02 | 2022-02-17 | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8026053B2 (https=) |
| EP (5) | EP2497836B1 (https=) |
| JP (10) | JP2007530017A (https=) |
| AU (2) | AU2005227148B2 (https=) |
| CA (1) | CA2560696C (https=) |
| CY (1) | CY1121975T1 (https=) |
| DK (3) | DK3556866T3 (https=) |
| ES (5) | ES2437590T3 (https=) |
| HU (1) | HUE045690T2 (https=) |
| LT (1) | LT3296407T (https=) |
| PL (2) | PL3296407T3 (https=) |
| PT (3) | PT1730303E (https=) |
| SI (2) | SI3296407T1 (https=) |
| WO (1) | WO2005091849A2 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011505124A (ja) * | 2007-12-03 | 2011-02-24 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Ｐｉｋ３ｃａ発現をモジュレーションするためのｒｎａアンタゴニスト化合物 |
| CN102816839A (zh) * | 2012-07-06 | 2012-12-12 | 杭州艾迪康医学检验中心有限公司 | 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒 |
| JP2016510982A (ja) * | 2013-03-13 | 2016-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ヒトｐｉ３ｋｃａ（ｐｉｋ３ｃａ）遺伝子変異検出のための方法及び組成物 |
| JP2016515390A (ja) * | 2013-04-05 | 2016-05-30 | ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ | 胃癌に対する予後予測模型の製造方法 |
| WO2018181863A1 (ja) * | 2017-03-30 | 2018-10-04 | 国立大学法人東京大学 | 異なる複数の目的遺伝子の評価方法 |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007530017A (ja) | 2004-03-02 | 2007-11-01 | ザ ジョンズ ホプキンス ユニバーシティ | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| EP1849877A1 (en) * | 2006-04-24 | 2007-10-31 | Erasmus University Medical Center Rotterdam | Replicative history of T-and B-cell subsets |
| WO2008109375A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof |
| GB2453173A (en) * | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| WO2009152346A2 (en) * | 2008-06-11 | 2009-12-17 | Intradigm Corporation | Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof |
| CN101445832B (zh) * | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| EP2553463B1 (en) | 2010-03-26 | 2017-05-03 | Hongzhi Zou | Methods and materials for detecting colorectal neoplasm |
| AU2011329180A1 (en) * | 2010-11-15 | 2013-05-02 | Enzon Pharmaceuticals, Inc. | Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides |
| JP2013545756A (ja) * | 2010-11-16 | 2013-12-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 投与および治療方法 |
| WO2012106175A1 (en) | 2011-02-02 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| ES2986436T3 (es) | 2011-04-15 | 2024-11-11 | Univ Johns Hopkins | Sistema de secuenciación segura |
| US20140298493A1 (en) * | 2011-07-28 | 2014-10-02 | Somasekar Seshagiri | PIK3CA H1047R Knock-In Non-Human Animal Breast Cancer Model |
| US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
| WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
| ES2886507T5 (es) | 2012-10-29 | 2024-11-15 | Univ Johns Hopkins | Prueba de Papanicolaou para cánceres de ovario y de endometrio |
| CA2902916C (en) | 2013-03-14 | 2018-08-28 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
| EP3027654B1 (en) * | 2013-07-30 | 2019-09-25 | Blueprint Medicines Corporation | Pik3c2g fusions |
| CN120700143A (zh) | 2014-03-31 | 2025-09-26 | 梅奥医学教育和研究基金会 | 检测结直肠赘生物 |
| DK3198026T3 (da) * | 2014-08-07 | 2020-01-20 | Pharmassist Ltd | Fremgangsmåde til bestemmelse af pik3ca-mutationsstatus i en prøve |
| US12391985B2 (en) | 2014-08-07 | 2025-08-19 | Pharmassist Ltd | Method of determining PIK3CA mutational status in a sample |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| CN104531854B (zh) * | 2014-11-10 | 2017-01-18 | 中国人民解放军第三〇七医院 | 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒 |
| US10030272B2 (en) | 2015-02-27 | 2018-07-24 | Mayo Foundation For Medical Education And Research | Detecting gastrointestinal neoplasms |
| US10435755B2 (en) | 2015-03-27 | 2019-10-08 | Exact Sciences Development Company, Llc | Detecting esophageal disorders |
| US10689710B2 (en) * | 2015-05-27 | 2020-06-23 | Quest Diagnostics Investments Incorporated | Methods for screening solid tumors for mutations |
| US11286531B2 (en) | 2015-08-11 | 2022-03-29 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| CN114574585A (zh) | 2015-08-31 | 2022-06-03 | 梅约医药教育及研究基金会 | 检测胃肿瘤 |
| RU2018123524A (ru) | 2015-12-03 | 2020-01-09 | Новартис Аг | Фармацевтическая диагностика |
| RU2608960C1 (ru) * | 2016-03-18 | 2017-01-27 | Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) | Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами |
| JP7481804B2 (ja) | 2016-04-14 | 2024-05-13 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 高度膵異形成の検出 |
| US10370726B2 (en) | 2016-04-14 | 2019-08-06 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasia |
| JP7356349B2 (ja) | 2017-02-28 | 2023-10-04 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 前立腺癌検出 |
| CN111868260B (zh) | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| JP7067896B2 (ja) | 2017-10-27 | 2022-05-16 | シスメックス株式会社 | 品質評価方法、品質評価装置、プログラム、および記録媒体 |
| JP7277460B2 (ja) | 2017-11-30 | 2023-05-19 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 乳癌の検出 |
| EP4103748A4 (en) | 2020-02-14 | 2024-03-13 | The Johns Hopkins University | METHOD AND MATERIALS FOR ASSESSING NUCLEIC ACIDS |
| CN111363827A (zh) * | 2020-04-30 | 2020-07-03 | 北京和合医学诊断技术股份有限公司 | 用于检测pik3ca基因突变的引物组及其应用方法 |
| DE102021126650A1 (de) | 2021-10-14 | 2023-04-20 | Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts | Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff |
| CN116219015A (zh) * | 2023-02-06 | 2023-06-06 | 中日友好医院(中日友好临床医学研究所) | 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248671A (en) * | 1989-02-15 | 1993-09-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| US5846624A (en) * | 1996-12-06 | 1998-12-08 | The Standard Register Company | Dual face pressure sensitive label |
| US6277563B1 (en) | 1997-01-16 | 2001-08-21 | The Regents Of The University Of California | Genetic alterations associated with cancer |
| US7670767B1 (en) * | 1997-01-16 | 2010-03-02 | The Regents Of The University Of California | Genetic alterations associated with cancer |
| US6558903B1 (en) | 1999-06-30 | 2003-05-06 | Millennium Pharmaceuticals, Inc. | Kinases and uses thereof |
| ATE388226T1 (de) * | 1999-08-27 | 2008-03-15 | Novartis Vaccines & Diagnostic | Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon |
| WO2001055301A2 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2002027028A1 (en) * | 2000-09-28 | 2002-04-04 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
| US20020142305A1 (en) | 2001-03-27 | 2002-10-03 | Koei Chin | Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers |
| US20030135033A1 (en) * | 2002-01-04 | 2003-07-17 | Anke Klippel-Giese | Compounds and methods for the identification and/ or validation of a target |
| JP2005533604A (ja) | 2002-07-25 | 2005-11-10 | アバンテック バスキュラー コーポレーション | 治療薬を送達する装置とこれに関する方法 |
| AU2004228668B2 (en) * | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| JP2007530017A (ja) | 2004-03-02 | 2007-11-01 | ザ ジョンズ ホプキンス ユニバーシティ | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
-
2005
- 2005-02-18 JP JP2007501815A patent/JP2007530017A/ja not_active Withdrawn
- 2005-02-18 DK DK19175606.3T patent/DK3556866T3/da active
- 2005-02-18 PT PT57232779T patent/PT1730303E/pt unknown
- 2005-02-18 PT PT17197306T patent/PT3296407T/pt unknown
- 2005-02-18 WO PCT/US2005/005193 patent/WO2005091849A2/en not_active Ceased
- 2005-02-18 PL PL17197306T patent/PL3296407T3/pl unknown
- 2005-02-18 EP EP12164819.0A patent/EP2497836B1/en not_active Expired - Lifetime
- 2005-02-18 PT PT191756063T patent/PT3556866T/pt unknown
- 2005-02-18 HU HUE17197306A patent/HUE045690T2/hu unknown
- 2005-02-18 AU AU2005227148A patent/AU2005227148B2/en not_active Expired
- 2005-02-18 CA CA2560696A patent/CA2560696C/en not_active Expired - Lifetime
- 2005-02-18 LT LTEP17197306.8T patent/LT3296407T/lt unknown
- 2005-02-18 ES ES05723277.9T patent/ES2437590T3/es not_active Expired - Lifetime
- 2005-02-18 ES ES12164819.0T patent/ES2537633T3/es not_active Expired - Lifetime
- 2005-02-18 ES ES15150891.8T patent/ES2663248T3/es not_active Expired - Lifetime
- 2005-02-18 US US10/591,347 patent/US8026053B2/en active Active
- 2005-02-18 SI SI200532262T patent/SI3296407T1/sl unknown
- 2005-02-18 DK DK17197306.8T patent/DK3296407T3/da active
- 2005-02-18 EP EP15150891.8A patent/EP2896703B1/en not_active Expired - Lifetime
- 2005-02-18 PL PL05723277T patent/PL1730303T3/pl unknown
- 2005-02-18 ES ES17197306T patent/ES2743125T3/es not_active Expired - Lifetime
- 2005-02-18 EP EP17197306.8A patent/EP3296407B1/en not_active Expired - Lifetime
- 2005-02-18 EP EP19175606.3A patent/EP3556866B1/en not_active Expired - Lifetime
- 2005-02-18 SI SI200531792T patent/SI1730303T1/sl unknown
- 2005-02-18 EP EP05723277.9A patent/EP1730303B1/en not_active Expired - Lifetime
- 2005-02-18 ES ES19175606T patent/ES2869167T3/es not_active Expired - Lifetime
- 2005-02-18 DK DK05723277.9T patent/DK1730303T3/da active
-
2011
- 2011-02-11 AU AU2011200600A patent/AU2011200600B2/en not_active Expired
- 2011-08-16 US US13/210,736 patent/US20110319477A1/en not_active Abandoned
-
2012
- 2012-03-09 JP JP2012052427A patent/JP5336620B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-10 JP JP2013100073A patent/JP5894110B2/ja not_active Expired - Lifetime
-
2014
- 2014-10-31 US US14/529,351 patent/US10422006B2/en not_active Expired - Lifetime
-
2015
- 2015-12-17 JP JP2015245769A patent/JP6250017B2/ja not_active Expired - Lifetime
-
2017
- 2017-10-19 JP JP2017202265A patent/JP6395917B2/ja not_active Expired - Lifetime
- 2017-12-08 US US15/836,366 patent/US10704105B2/en not_active Expired - Lifetime
-
2018
- 2018-05-09 JP JP2018090580A patent/JP6695381B2/ja not_active Expired - Lifetime
-
2019
- 2019-08-21 CY CY20191100895T patent/CY1121975T1/el unknown
- 2019-10-07 US US16/595,055 patent/US11549150B2/en not_active Expired - Lifetime
- 2019-11-06 JP JP2019201128A patent/JP6694543B2/ja not_active Expired - Lifetime
-
2020
- 2020-03-06 JP JP2020038337A patent/JP7169315B2/ja not_active Expired - Lifetime
- 2020-04-20 US US16/853,230 patent/US10787713B2/en not_active Expired - Lifetime
- 2020-04-28 JP JP2020078786A patent/JP7001735B2/ja not_active Expired - Lifetime
-
2022
- 2022-02-17 JP JP2022022542A patent/JP7304987B2/ja not_active Expired - Lifetime
Non-Patent Citations (5)
| Title |
|---|
| JPN6010056030, "Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ", ２００３， Ｖｏｌ．６３， ｐｐ．４２２５−４２３１ * |
| JPN6010056031, "Ｏｎｃｏｇｅｎｅ", ２０００， Ｖｏｌ．１９， ｐｐ．２７３９−２７４４ * |
| JPN6010056032, "Ｎａｔｕｒｅ Ｇｅｎｅｔｉｃｓ", １９９９， Ｖｏｌ．２１， ｐｐ．９９−１０２ * |
| JPN6010056033, "Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ", ２０００， Ｖｏｌ．２７５， Ｎｏ．６， ｐｐ．３７４１−３７４４ * |
| JPN6010056035, "Ｐｒｏｃｅｅｄｉｎｇｓ． Ａｎｎｕａｌ Ｍｅｅｔｉｎｇ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ａｓｓｏｃｉａｔｉｏｎ ｆｏｒ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ", ２００２， Ｖｏｌ．４３， ｐ．６０２ * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011505124A (ja) * | 2007-12-03 | 2011-02-24 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Ｐｉｋ３ｃａ発現をモジュレーションするためのｒｎａアンタゴニスト化合物 |
| CN102816839A (zh) * | 2012-07-06 | 2012-12-12 | 杭州艾迪康医学检验中心有限公司 | 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒 |
| JP2016510982A (ja) * | 2013-03-13 | 2016-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ヒトｐｉ３ｋｃａ（ｐｉｋ３ｃａ）遺伝子変異検出のための方法及び組成物 |
| JP2016515390A (ja) * | 2013-04-05 | 2016-05-30 | ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ | 胃癌に対する予後予測模型の製造方法 |
| WO2018181863A1 (ja) * | 2017-03-30 | 2018-10-04 | 国立大学法人東京大学 | 異なる複数の目的遺伝子の評価方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7304987B2 (ja) | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 | |
| HK40016239B (en) | Mutations of the pik3ca gene in human cancers | |
| HK40016239A (en) | Mutations of the pik3ca gene in human cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110902 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120309 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120423 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120420 |